文献速递免疫规划传染病防控与疫情报告

含麻疹腮腺炎风疹疫苗在健康幼儿中的10年长期免疫原性随访

Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
PubMed 文献 · Vaccine · 2019-07-22

本研究对1887名12–22月龄健康儿童随机接种1剂或2剂含MMR疫苗(Priorix或Priorix-Tetra)后进行10年抗体持久性分析。结果显示麻疹和风疹抗体10年后仍高于血清阳性阈值,腮腺炎抗体相对稳定且第二剂有加强作用。

要点

  • 麻疹和风疹抗体10年后仍高于血清阳性阈值。
  • Priorix-Tetra诱导的麻疹抗体滴度约为Priorix的2倍。
  • 第二剂MMR对腮腺炎抗体有加强作用。

核心结论

  • 幼儿第二年内接种1剂或2剂含MMR疫苗诱导的麻疹、腮腺炎和风疹抗体反应至少持续至接种后10年。

研究设计与样本

  • 10年随访研究纳入1887名12–22月龄健康儿童,随机接种1剂或2剂含MMR疫苗(Priorix或Priorix-Tetra;GSK),进行抗体持久性分析。
  • 1剂组中364名儿童在第1剂后4–10年按当地接种程序于研究外接种第二剂,纳入事后分析评估延迟第二剂效果。

主要发现

  • 接种后麻疹和风疹抗体适度下降,但10年后仍远高于血清阳性阈值。
  • 整个研究期间Priorix-Tetra诱导的抗麻疹抗体滴度约为Priorix的2倍。
  • 后期第二剂MMR对麻疹和风疹抗体下降滴度影响轻微且短暂。
  • 抗腮腺炎抗体水平在10年随访中相对稳定,10年内任何时间接种第二剂MMR对腮腺炎抗体滴度和血清阳性率均有加强效果。

临床怎么用

  • 健康幼儿第二年内接种含MMR疫苗可提供至少10年的麻疹、腮腺炎和风疹抗体持久性。
  • 延迟接种第二剂MMR对腮腺炎抗体有加强作用,对麻疹和风疹抗体下降影响有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Measles and mumps outbreaks still occur in countries that have successfully implemented universal routine immunization programs. Measles outbreaks are mostly associated to absent or incomplete vaccination, whereas for mumps outbreaks the combined effects of waning of immunity and circulating new strains are incriminated. It is therefore increasingly useful to characterize the long-lasting immunity induced by measles-, mumps, and rubella (MMR)-containing vaccines. In this 10-year study, 1887 healthy children aged 12-22 months, randomized to receive 1 or 2 doses of MMR-containing vaccines (Priorix or Priorix-Tetra; GSK), were included in an antibody persistence analysis. A total of 364 children in the 1-dose group received a second dose out of study according to their local vaccination schedule between Years 4 and 10 post-dose 1, and were included in a separate post-hoc analysis to evaluate the effect of the second dose when given later. Anti-measles, -mumps and -rubella antibody titers were measured by commercial ELISA kits (Enzygnost, Siemens) after each vaccine dose and at Years 1, 2, 4, 6, 8 and 10 post-vaccination. Antibodies against measles and rubella declined moderately after vaccination but remained well above the seropositivity threshold after 10 years. The anti-measles antibody titers elicited by Priorix-Tetra remained about 2-fold higher throughout the study as compared with Priorix. A second dose of MMR vaccine later in life had a minor and transient effect on anti-measles and anti-rubella waning titers. In contrast, anti-mumps antibody levels remained relatively stable over the 10-year follow-up and a second dose of MMR vaccine, given anytime over the 10-year period, had a boosting effect on anti-mumps antibody titers and seropositivity rates. In conclusion, 1 or 2 doses of MMR-containing vaccines given to children in their second year of life induced antibody responses against measles, mumps and rubella viruses that persisted at least up to 10 years post-vaccination. Clinical trial registration number: NCT00226499.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Carryn S, Feyssaguet M, Povey M, et al. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up. Vaccine. 2019. PMID: 31345639. doi:10.1016/j.vaccine.2019.07.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。